Heart Tumor Market Research Report-  Forecast till 2027

Heart Tumor Market: By Type (Primary Tumor, Secondary Tumor) By Diagnosis (CT, MRI, Radionuclide Imaging, PET, Myocardial Biopsy, Cardiac Catherization, Electrophysiology Test) By Treatment (Surgery, Chemotherapy, Radiotherapy)-Forecast Till 2027

ID: MRFR/MED/3629-HCR | | Region: Global | 85 pages

Heart Tumor Market Scenario


Cardiac tumors is a rare disease that aredifficult to diagnose. They are divided on the basis of type into primary and secondary tumors. The prevalance of the secondary tumors is higher than the primary tumors. Majority of the primary cardiac tumors are benign in origin. The high incidences of metastatic tumors  is attributed to various types of  cancers such as lung, breast, renal cancer, lymphomas and melanomas. Clinical manifestations of these tumors generally based on  the size and location of the tumors and spread to the adjacent tissues rather than the type of the tumor itself.  Echocardiography is the major tool used for diagnosis of the tumors. Other imaging modalities include cardiac MRI, cardiac CT, and 3D echocardiography, which may offer some additional information with histological examination. According to the surgery and autopsy reports, primary cardiac tumors are rare with an incidence rate of about 0.3%-0.7%. Malignant primary cardiac sarcomas are usually located in the right atrium of the heart and are most commonly angiosarcomas. The malignant primary cardiac tumors are often diagnosed in young patientswho have a poor prognosis and survival rate of only 10% According to the WHO, the prevalence of melanoma skin cancers has been increasing from the past few decades. Furthermore, 132,000 melanoma skin cancers cases are reported each year across the globe. A small percentage of cardiac tumor cases are hereditary, the tumors can also be associated with another health condition, such as LAMB Syndrome, Carney Syndrome or NAME Syndrome. However, most often, the tumor develops without being associated with any health condition or presence of a family history. They result from cell overgrowth but mostly cardiac tumors results from metastatic condition, where cells from other cancerous organ such as lung and breast, soft-tissues and metastasizes to the heart. Myxoma is the most common primary cardiac tumor accounting for 50% of all the cardiac tumors. Incidences of myxoma in women is 2 to 4 times more than men. About 75% of myxomas occur in the left atrium and the rest occur in the other chambers as a solid tumor or, less commonly, at several other sites. Myxomas can grow upto 15 cm in diameter. Removal requires open heart surgery and in many cases it can be done robotically or using a minimally invasive technique. The hospital stay is likely to be shorten if sugery is done robotically or by minimally invasive approach.  Successful recovery is rare. After surgery, echocardiogram is required to be done every year to make sure that the tumor has not returned and that there are no new growth.


The Global Heart Tumor Market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.


Heart Tumor Market Key Players


Some of key the players in the Global heart tumor market are Tomtec Imaging Systems GmBh, Koninklijke Philips N.V., Siemens Healthineers, Circle Cardiovascular Imaging Inc., Toshiba Corporation, Shimadzu Corporation, CardioComm Solutions Inc., Integer Holdings Corporation, Pie Medical Imaging, HeartSciences, 3mensio Medical Imaging, and eMedica, S.L. 


Heart Tumor Market Segmentation


The heart tumor market is segmented on the basis of type, diagnosis, treatment.


On the basis of the type, the heart tumor market is segmented into primary tumors and secondary tumors. The primary tumors are divided into benign and malignant. The benign tumors is further categorized into myxoma, papillary heart tumors, fibromas, rhabdomyomas, angioma, and lipomas. The malignant tumors are divided into rhabdomyosarcoma, mesenchymomas, neurosarcoma, fusiform cell tumors, malignant heart hemangioma, and lymphosarcoma. The secondary tumor is categorized into metastatic and contiguity. The metastatic secondary tumors are divided into hematogenic and lymphatic and the contiguity is sub categorized into mediastinal tumors, lung tumors and oesophageal, or cardia tumor.


On the basis of the diagnosis, the heart tumor market is classified into echocardiogram, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), radionuclide imaging, Position Emission Tomography (PET) Scan, myocardial biopsy, cardiac catherization, and electrophysiology test.


On the basis of the treatment, the heart tumor market is classified into surgery, chemotherapy, radiation therapy. Furthermore, the surgery is further categorized into open heart surgery, minimal invasive surgery, and heart transplant surgery 


International Heart Tumor Market Regional Analysis


The global heart tumor market consists of four major regions: the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominate the heart tumor market owing to the rising awareness among people and increasing healthcare expenditure. The type of tumors also aids in selection of treatment procedure. For instance, in patient with heart cancers, the results of cardiac imaging could be used to see if the the tumor is spread to the adjacent tissues, which can be further used to remove the portion by performing excision surgery or pursuing treatment with medications. The growing demand for outpatient surgeries and increasing preference of specialized cardiac imaging devices are some of the major factors intended to cost-effective technology, which further drives the demand for heart tumor market in the European region. Increasing prevalence of metastatic tumors, which require surgical procedures and growing medical tourism in Asia Pacific region are favoring the growth of this market. According to the WHO estimate, 75% of the cardiovascular diseases occur are in low and middle income regions including Asia Pacific and the Middle East and Africa regions.


Intended Audience



  • Hospitals

  • Imaging Device Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Research Methodology

Heart Tumor Market


Sources: Annual reports, Press release, White paper, and Company presentation





Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2019-2023: 7.1%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, diagnosis, treatment
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Tomtec Imaging Systems GmBh, Koninklijke Philips N.V., Siemens Healthineers, Circle Cardiovascular Imaging Inc., Toshiba Corporation, Shimadzu Corporation, CardioComm Solutions Inc., Integer Holdings Corporation, Pie Medical Imaging, HeartSciences, 3mensio Medical Imaging, and eMedica, S.L.
  Key Market Opportunities   Research and Development
  Key Market Drivers   Increasing prevalence of metastatic tumors


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Heart tumor market CAGR would be 7.1% during the forecast period.

Heart tumor market players are HeartSciences, 3mensio Medical Imaging, Koninklijke Philips N.V., Circle Cardiovascular Imaging Inc., Siemens Healthineers, Toshiba Corporation, Tomtec Imaging Systems GmBh, Shimadzu Corporation, Integer Holdings Corporation, CardioComm Solutions Inc., Pie Medical Imaging, and eMedica, S.L.

The treatment types of the heart tumor market are chemotherapy, surgery, and radiation therapy.

The Americas would lead the global heart tumor market.

The diagnosis mentioned in the heart tumor market are Computed Tomography (CT) scan, echocardiogram, myocardial biopsy, radionuclide imaging, Position Emission Tomography (PET) Scan, cardiac catherization, Magnetic Resonance Imaging (MRI), and electrophysiology test.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Heart Tumor Market, By Type

6.1 Introduction

6.2 Primary Tumor

6.2.1 Market Estimates & Forecast, 2020 – 2023

6.2.2 Benign

6.2.2.1 Market Estimates & Forecast, 2020 – 2023

6.2.2.2 Myxoma

6.2.2.2.1 Market Estimates & Forecast, 2020 – 2023

6.2.2.3 Papillary Heart Tumors

6.2.2.3.1 Market Estimates & Forecast, 2020 – 2023

6.2.2.4 Fibromas

6.2.2.4.1 Market Estimates & Forecast, 2020 – 2023

6.2.2.5 Rhabdomyomas

6.2.2.5.1 Market Estimates & Forecast, 2020 – 2023

6.2.2.6 Angioma

6.2.2.6.1 Market Estimates & Forecast, 2020 – 2023

6.2.2.7 Lipomas

6.2.2.7.1 Market Estimates & Forecast, 2020 – 2023

6.2.3 Malignant

6.2.3.1 Market Estimates & Forecast, 2020 – 2023

6.2.3.2 Rhabdomyosarcoma

6.2.3.2.1 Market Estimates & Forecast, 2020 – 2023

6.2.3.3 Mesenchymomas

6.2.3.3.1 Market Estimates & Forecast, 2020 – 2023

6.2.3.4 Neurosarcoma

6.2.3.4.1 Market Estimates & Forecast, 2020 – 2023

6.2.3.5 Fusiform Cell Tumors

6.2.3.5.1 Market Estimates & Forecast, 2020 – 2023

6.2.3.6 Malignant Heart Hemangioma

6.2.3.6.1 Market Estimates & Forecast, 2020 – 2023

6.2.3.7 Lymphosarcoma

6.2.3.7.1 Market Estimates & Forecast, 2020 – 2023

6.3 Secondary Tumor

6.3.1 Market Estimates & Forecast, 2020 – 2023

6.3.2 Metastatic

6.3.2.1 Market Estimates & Forecast, 2020 – 2023

6.3.2.2 Hematogenic

6.3.2.2.1 Market Estimates & Forecast, 2020 – 2023

6.3.2.3 Lymphatic

6.3.2.3.1 Market Estimates & Forecast, 2020 – 2023

6.3.3 Contiguity

6.3.3.1 Market Estimates & Forecast, 2020 – 2023

6.3.3.2 Mediastinal Tumors

6.3.3.2.1 Market Estimates & Forecast, 2020 – 2023

6.3.3.3 Lung Tumors

6.3.3.3.1 Market Estimates & Forecast, 2020 – 2023

6.3.3.4 Oesophageal Or Cardia Tumor.

6.3.3.4.1 Market Estimates & Forecast, 2020 – 2023

Chapter 7. Global Heart Tumor Market, By Diagnosis

7.1 Introduction

7.2 Echocardiogram

7.2.1 Market Estimates & Forecast, 2020 – 2027

7.3 Computed Tomography (CT) Scan

7.3.1 Market Estimates & Forecast, 2020 – 2027

7.4 Magnetic Resonance Imaging (MRI)

7.4.1 Market Estimates & Forecast, 2020 – 2027

7.5 Radionuclide Imaging

7.5.1 Market Estimates & Forecast, 2020 – 2027

7.6 Position Emission Tomography (PET) Scan

7.6.1 Market Estimates & Forecast, 2020 – 2027

7.7 Myocardial Biopsy

7.7.1 Market Estimates & Forecast, 2020 – 2027

7.8 Cardiac Catherization

7.8.1 Market Estimates & Forecast, 2020 – 2027

7.9 Electrophysiology Test

7.9.1 Market Estimates & Forecast, 2020 – 2027

Chapter 8. Global Heart Tumor Market, By Treatment

8.1 Introduction

8.2 Surgery

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.2.2 Open Heart Surgery

8.2.2.1 Market Estimates & Forecast, 2020 – 2027

8.2.3 Minimal Invasive Surgery

8.2.3.1 Market Estimates & Forecast, 2020 – 2027

8.2.4 Heart Transplant Surgery

8.2.4.1 Market Estimates & Forecast, 2020 – 2027

8.3 Chemotherapy,

8.3.1 Market Estimates & Forecast, 2020 – 2027

8.4 Radiation Therapy

8.4.1 Market Estimates & Forecast, 2020 – 2027

Chapter .9 Global Heart Tumor Market, By Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest Of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic Of Korea

9.4.6 Rest Of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest Of The Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 TOMTEC IMAGING SYSTEMS GMBH

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Koninklijke Philips N.V.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Siemens Healthineers

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Circle Cardiovascular Imaging Inc.

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Toshiba Corporation.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial Overview

11.5.4 Key Developments

11.6 Shimadzu Corporation

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 CardioComm Solutions Inc.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Integer Holdings Corporation

11.48.1 Company Overview

11.48.2 Product/Business Segment Overview

11.48.3 Financial Overview

11.48.4 Key Development

11.48.5 SWOT Analysis

11.9 Pie Medical Imaging

11.59.1 Company Overview

11.59.2 Product Overview

11.59.3 Financial Overview

11.59.4 Key Developments

11.10 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs Of The Market

12.2 Key Companies To Watch

12.3 Prediction Of Pharmaceutical Industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Heart Tumor Industry Synopsis, 2020 – 2027

Table 2 Heart Tumor Market Estimates And Forecast, 2020 – 2027, (USD Million)

Table 3 Heart Tumor Market By Region, 2020 – 2027, (USD Million)

Table 4 Heart Tumor Market By Type, 2020 – 2027, (USD Million)

Table 5 Heart Tumor Market By Diagnosis, 2020 – 2027, (USD Million)

Table 6 Heart Tumor Market By Treatment, 2020 – 2027, (USD Million)

Table 7 North America Heart Tumor Market By Type, 2020 – 2027, (USD Million)

Table 8 North America Heart Tumor Market By Diagnosis, 2020 – 2027, (USD Million)

Table 9 North America Heart Tumor Market By Treatment, 2020 – 2027, (USD Million)

Table 10 US Heart Tumor Market By Type, 2020 – 2027, (USD Million)

Table 11 US Heart Tumor Market By Diagnosis, 2020 – 2027, (USD Million)

Table 12 US Heart Tumor Market By Treatment, 2020 – 2027, (USD Million)

Table 13 Canada Heart Tumor Market By Type, 2020 – 2027, (USD Million)

Table 14 Canada Heart Tumor Market By Diagnosis, 2020 – 2027, (USD Million)

Table 15 Canada Heart Tumor Market By Treatment, 2020 – 2027, (USD Million)

Table 16 South America Heart Tumor Market By Type, 2020 – 2027, (USD Million)

Table 17 South America Heart Tumor Market By Diagnosis, 2020 – 2027, (USD Million)

Table 18 South America Heart Tumor Market By Treatment, 2020 – 2027, (USD Million)

Table 19 Europe Heart Tumor Market By Type, 2020 – 2027, (USD Million)

Table 20 Europe Heart Tumor Market By Diagnosis, 2020 – 2027, (USD Million)

Table 21 Europe Heart Tumor Market By Treatment, 2020 – 2027, (USD Million)

Table 22 Western Europe Heart Tumor Market By Type, 2020 – 2027, (USD Million)

Table 23 Western Europe Heart Tumor Market By Diagnosis, 2020 – 2027, (USD Million)

Table 24 Western Europe Heart Tumor Market By Treatment, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Heart Tumor Market By Type, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Heart Tumor Market By Diagnosis, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Heart Tumor Market By Treatment, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Heart Tumor Market By Type, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Heart Tumor Market By Diagnosis, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Heart Tumor Market By Treatment, 2020 – 2027, (USD Million)

Table 31 Middle East & Africa Heart Tumor Market By Type, 2020 – 2027, (USD Million)

Table 32 Middle East & Africa Heart Tumor Market By Diagnosis, 2020 – 2027, (USD Million)

Table 33 Middle East & Africa Heart Tumor Market By Treatment, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation For Heart Tumor Market

Figure 3 Segmentation Market Dynamics For Heart Tumor Market

Figure 4 Global Heart Tumor Market Share, By Type 2020

Figure 5 Global Heart Tumor Market Share, By Diagnosis 2020

Figure 6 Global Heart Tumor Market Share, By Treatment, 2020

Figure 7 Global Heart Tumor Market Share, By Region, 2020

Figure 8 North America Heart Tumor Market Share, By Country, 2020

Figure 9 Europe Heart Tumor Market Share, By Country, 2020

Figure 10 Asia Pacific Heart Tumor Market Share, By Country, 2020

Figure 11 Middle East & Africa Heart Tumor Market Share, By Country, 2020

Figure 12 Global Heart Tumor Market: Company Share Analysis, 2020 (%)

Figure 13 TOMTEC IMAGING SYSTEMS GMBH: Key Financials

Figure 14 TOMTEC IMAGING SYSTEMS GMBH: Segmental Revenue

Figure 15 TOMTEC IMAGING SYSTEMS GMBH: Geographical Revenue

Figure 16 Koninklijke Philips N.V.: Key Financials

Figure 17 Koninklijke Philips N.V.: Segmental Revenue

Figure 18 Koninklijke Philips N.V.: Geographical Revenue

Figure 19 Siemens Healthineers: Key Financials

Figure 20 Siemens Healthineers: Segmental Revenue

Figure 21 Siemens Healthineers: Geographical Revenue

Figure 22 Circle Cardiovascular Imaging Inc: Key Financials

Figure 23 Circle Cardiovascular Imaging Inc: Segmental Revenue

Figure 24 Circle Cardiovascular Imaging Inc: Geographical Revenue

Figure 25 Toshiba Corporation: Key Financials

Figure 26 Toshiba Corporation: Segmental Revenue

Figure 27 Toshiba Corporation: Geographical Revenue

Figure 28 Shimadzu Corporation.: Key Financials

Figure 29 Shimadzu Corporation: Segmental Revenue

Figure 30 Shimadzu Corporation: Geographical Revenue

Figure 31 CardioComm Solutions Inc: Key Financials

Figure 32 CardioComm Solutions Inc: Segmental Revenue

Figure 33 CardioComm Solutions Inc: Geographical Revenue

Figure 34 Integer Holdings Corporation: Key Financials

Figure 35 Integer Holdings Corporation: Segmental Revenue

Figure 36 Integer Holdings Corporation: Geographical Revenue

Figure 37 Pie Medical Imaging: Key Financials

Figure 38 Pie Medical Imaging: Segmental Revenue

Figure 39 Pie Medical Imagingv: Geographical Revenue